ReviewCurrent cardiology reports2020
Challenges and Controversies in the Management of ACS in Elderly Patients.
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Predictive Value of Serum Pepsinogen and Gastrin-17 in Patients With Acute Coronary Syndrome for Post-Percutaneous Coronary Intervention Oral Dual Antiplatelet Therapy-Associated Upper Gastrointestinal Bleeding.Cardiovascular therapeutics · 2026Article
- Circulating exosomal miR-20b-5p and miR-1273g-3p were potential biomarkers for diagnosis and prognosis of acute coronary syndrome.Cardiovascular diagnosis and therapy · 2025Article
- Clinical Outcomes After Immediate Coronary Angiography in Elderly Versus Younger Patients Suffering from Acute Coronary Syndrome.Journal of cardiovascular development and disease · 2025Article
- Serum Albumin-to-Creatinine Ratio Predicts One-Year Mortality in Elderly Patients with Non-ST-Elevation Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Prospective Cohort Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.Nature reviews. Cardiology · 2023Review
- Geriatric nutritional risk index predicts all-cause mortality in the oldest-old patients with acute coronary syndrome: A 10-year cohort study.Frontiers in nutrition · 2023Article
- Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2022Review
- A Case of Acute Non-ST Elevation Myocardial Infarction Later Revealed by Contrast-Enhanced Computed Tomography.The American journal of case reports · 2022Article
- Acute coronary syndromes.Lancet (London, England) · 2022Review
- Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome.Journal of geriatric cardiology : JGC · 2021Article
- Not All STEMI Patients Receive Timely Reperfusion: Considerations for Rural Emergency Departments.Journal of multidisciplinary healthcare · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewElderly patients presenting with acute coronary syndrome (ACS) represent a challenging patient population. A high index of suspicion is needed for their diagnosis, as they are less likely to present with typical anginal symptoms compared to their younger counterparts. RECENT
findingsDisrupted coronary plaques with superimposed thrombosis are the predominant pathophysiology of ACS; however, an increased proportion of calcified nodules is encountered in elderly patients. Emergent reperfusion and revascularization remain the mainstay treatment for ST-elevation myocardial infarction or cardiogenic shock. In elderly patients with NSTE-ACS, a routine invasive strategy is generally superior to an ischemia-guided strategy, and the safety of an early invasive strategy has also been recently demonstrated. When treating elderly ACS patients with antiplatelet and antithrombotic therapies, close attention to co-morbidities, frailty and the balance of ischemia-bleeding risk should be undertaken, and medication doses should be carefully adjusted. Overall, elderly patients with ACS remain undertreated with evidence-based therapies, experience worse outcomes, and represent an opportunity for enhancing and mitigating healthcare disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.